Medical Disclaimer: This site provides informational comparisons only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician or pharmacist before making medication decisions.
Brand names: Skyrizi
Humanized monoclonal antibody that selectively binds to the p19 subunit of IL-23, inhibiting IL-23-dependent inflammatory signalling.
8 documented side effects by frequency
No community discussions found for Risankizumab yet.
18 available comparisons
Dosage Forms
Injection
Route
Subcutaneous